Newer glucose-lowering agents such as glucagon-like peptide 1 receptor agonists (GLP-1 RA) or sodium-glucose-like cotransporter 2 inhibitors (SGLT2i) have established cardiovascular disease benefits [13, 14]. The gene discussed is GLP1R; the disease is cardiovascular disorder.